5:59 PM
 | 
Jan 14, 2013
 |  BC Extra  |  Company News

FDA to discuss risk/benefit of calcitonin salmon for osteoporosis

FDA's Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee will meet on March 5 to discuss whether the benefit of calcitonin salmon for postmenopausal osteoporosis outweighs...

Read the full 145 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >